PRELUDE THERAPEUTICS INC's ticker is PRLD and the CUSIP is 74065P101. A total of 70 filers reported holding PRELUDE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $31,282,616 | -31.3% | 10,123,824 | 0.0% | 0.18% | -31.8% |
| Q2 2023 | $45,557,208 | -21.1% | 10,123,824 | 0.0% | 0.26% | -15.9% |
| Q1 2023 | $57,705,797 | -5.6% | 10,123,824 | 0.0% | 0.31% | -14.4% |
| Q4 2022 | $61,147,897 | -8.6% | 10,123,824 | 0.0% | 0.37% | -16.2% |
| Q3 2022 | $66,918,000 | +26.6% | 10,123,824 | 0.0% | 0.44% | +46.0% |
| Q2 2022 | $52,846,000 | -24.3% | 10,123,824 | 0.0% | 0.30% | -25.2% |
| Q1 2022 | $69,854,000 | -44.6% | 10,123,824 | 0.0% | 0.40% | -34.6% |
| Q4 2021 | $126,042,000 | -60.2% | 10,123,824 | 0.0% | 0.61% | -55.9% |
| Q3 2021 | $316,370,000 | +9.2% | 10,123,824 | 0.0% | 1.39% | +9.1% |
| Q2 2021 | $289,845,000 | -33.9% | 10,123,824 | 0.0% | 1.27% | -33.1% |
| Q1 2021 | $438,665,000 | -39.4% | 10,123,824 | +0.1% | 1.90% | -30.3% |
| Q4 2020 | $723,988,000 | +137.5% | 10,118,636 | 0.0% | 2.73% | +124.0% |
| Q3 2020 | $304,875,000 | – | 10,118,636 | – | 1.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Orbimed Advisors | 10,039,691 | $66,362,000 | 1.23% |
| Baker Brothers Advisors | 10,123,824 | $66,918,000 | 0.44% |
| HHLR ADVISORS, LTD. | 583,333 | $3,856,000 | 0.10% |
| CAXTON ASSOCIATES LP | 85,992 | $568,000 | 0.08% |
| Virtus ETF Advisers LLC | 24,180 | $160,000 | 0.06% |
| GSA CAPITAL PARTNERS LLP | 54,173 | $358,000 | 0.05% |
| DENALI ADVISORS LLC | 8,200 | $54,000 | 0.03% |
| PDT Partners, LLC | 12,641 | $84,000 | 0.01% |
| UBS ASSET MANAGEMENT AMERICAS LLC | 2,402,595 | $15,881,153,000 | 0.01% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 36,949 | $244,000 | 0.01% |